Moleculin Biotech, Inc.
MBRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$6.50
KIRA · Stoqly’s AI analyst, in plain words
- Moleculin Biotech, Inc. had $0.0M of revenue in fiscal 2025.
- Moleculin Biotech, Inc. lost $33.6M in fiscal 2025.
- Free cash flow was −$22.7M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$33.6M
Free cash flow
−$22.7M
Operating margin
—
Moleculin Biotech, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$33.6M
No. It lost money last year.
What Moleculin Biotech, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- Moleculin Biotech, Inc.
- CIK
- 0001659617
Moleculin Biotech, Inc. · MBRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net interest income | $0.3M | $0.2M | — | — | — |
| Net income | −$15.9M | −$29.0M | −$29.8M | −$26.0M | −$33.6M |
| Diluted EPS | −$0.59 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$19.0M | −$27.6M | −$23.6M | −$23.9M | −$22.7M |
| Capital expenditure | $0.0M | $0.1M | $0.1M | $0.0M | $0.0M |
| Free cash flow | −$19.0M | −$27.7M | −$23.7M | −$23.9M | −$22.7M |
| Share count change | 173.0% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $70.9M | $43.1M | $23.6M | $4.3M | $8.9M |
| Shareholders' equity | $79.0M | $52.2M | $30.9M | $11.2M | $15.0M |
| Current ratio | 20.0x | 9.5x | 3.9x | 1.0x | 1.4x |
| Returns and quality | |||||
| Return on equity | −32.9% | −44.3% | −71.6% | −123.6% | −256.0% |
| Return on tangible equity | −20.1% | −55.6% | −96.3% | −232.4% | −224.3% |
| Piotroski F-score | 2 | — | — | — | — |
| Altman Z'' | 17.0 | 5.8 | −10.4 | −41.8 | −34.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Moleculin Biotech, Inc. · MBRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.50 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001659617). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.